Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | GPR183 | P32249 | 1/20 | 0.31 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL8813205 | 0.95 | MEN1 (0.53) | MEN1LMNAKMT2A | |
| Deanol SCHEMBL6665643 | 0.82 | MEN1 (0.35) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL571834 | 0.81 | MEN1 (0.77) | MEN1LMNAKMT2ATNNC1S1PR1 | |
| Tromethamine SCHEMBL1019777 | 0.81 | MEN1 (0.77) | MEN1LMNAKMT2ATNNC1S1PR1 | |
| Tromethamine SCHEMBL3705445 | 0.78 | MEN1 (0.71) | MEN1LMNAKMT2ATNNC1S1PR1 | |
| Tromethamine SCHEMBL1759319 | 0.78 | MEN1 (0.71) | MEN1LMNAKMT2ATNNC1S1PR1 | |
| Tromethamine SCHEMBL7193959 | 0.77 | MEN1 (0.83) | MEN1LMNAKMT2ATNNC1S1PR1 | |
| Tromethamine SCHEMBL28216031 | 0.77 | MEN1 (0.83) | MEN1LMNAKMT2ATNNC1S1PR1 | |
| Tromethamine SCHEMBL975 | 0.77 | — | — | |
| Tromethamine SCHEMBL3696191 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3849616-B1 | DRUG DELIVERY SYTEM FOR PLATINUM-BASED DRUGS | INST NAT SANTE RECH MED (FR) | 2022-07-13 | — | — | EP | disclosed |
| US-20220054424-A1 | DRUG DELIVERY SYSTEM | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-02-24 | — | — | US | disclosed |
| EP-3849616-A1 | DRUG DELIVERY SYTEM FOR PLATINUM-BASED DRUGS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020053445-A1 | DRUG DELIVERY SYTEM FOR PLATINUM-BASED DRUGS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-03-19 | — | — | WO | disclosed |
| US-20080213349-A1 | Liposome Complexes Containing Pharmaceutical Agents and Methods | MEDTRONIC, INC. | 2008-09-04 | — | — | US | disclosed |
| EP-0582707-B1 | BRANCHED AROMATIC CARBONATE POLYMER | GEN ELECTRIC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-5573752-A | Aromatic amide compounds and metal chelates thereof | BRACCO INTERNATIONAL B.V. | 1996-11-12 | — | — | US | disclosed |
| EP-0702677-A1 | AROMATIC AMIDE COMPOUNDS AND METAL CHELATES THEREOF | BRACCO International B.V. (NL) | 1996-03-27 | — | — | EP | disclosed |
| WO-1995027705-A1 | AROMATIC AMIDE COMPOUNDS AND METAL CHELATES THEREOF | BRACCO INTERNATIONAL B.V. (NL) | 1995-10-19 | — | — | WO | disclosed |
| EP-0582707-A1 | BRANCHED AROMATIC CARBONATE POLYMER | GENERAL ELECTRIC COMPANY (US) | 1994-02-16 | — | — | EP | disclosed |
| US-5262511-A | Branched aromatic carbonate polymer | GENERAL ELECTRIC CO. (US) | 1993-11-16 | — | — | US | disclosed |
| WO-1993018082-A1 | BRANCHED AROMATIC CARBONATE POLYMER | GENERAL ELECTRIC COMPANY (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054424-A1 | DRUG DELIVERY SYSTEM | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CD44, SLC3A2 | MEN1 3204/4885LMNA 1688/4885KMT2A 1637/4885 |
| US-20080213349-A1 | Liposome Complexes Containing Pharmaceutical Agents and Methods | NEU1, SIGLEC7, LIPA | MEN1 666/4885LMNA 500/4885KMT2A 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.